SK Biopharmaceuticals, solid growth and entry into the Chinese market… Target price of KRW 130,000 [EBest Investment & Securities]
SK Biopharmaceuticals, solid growth and entry into the Chinese market… Target price of KRW 130,000 [EBest Investment & Securities]
  • 이동훈 기자
  • 승인 2021.11.12 11:04
  • 최종수정 2021.11.12 08:56
  • 댓글 0
이 기사를 공유합니다

 

sk바이오팜 CI
sk바이오팜 CI

eBest Investment & Securities said it will offer its investment opinion "Buy" and target stock price of 130,000 won for SK Biopharmaceuticals.

This is because it is recording solid growth and is increasing the brand value of the global value chain by entering the Chinese market.

"SK Biopharmaceuticals' third-quarter earnings recorded sales of 23.95 billion won and operating profit of -49.94 billion won,"Ebest Investment & Securities said on the 12th. "Sales were in line with the consensus, but its operating profit was slightly below the consensus. Sales were about 94% of the guidance offered at the beginning of the year.".

Sales growth is expected to continue in the fourth quarter. The decision is based on the judgment that there are no risk factors except for some factors such as the inability to operate due to the spread of Delta and wholesale inventory policies. Annual earnings in 2021 are expected to reach 333.3 billion won in sales and -42.5 billion won in operating profit.

"SK Biopharmaceuticals has secured a Chinese marketing platform through the establishment of a joint venture in China,"said Ebest Investment & Securities "SK Biopharmaceuticals is the first step into the Chinese market to increase the brand value of the global value chain.".

Reporter Lee Dong-hoon usinvestmentidea2020@gmail.com


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.